Ahmedabad, May 02, 2017:Healthcare player Zydus Cadila informed about receiving the final approval from the US drug regulator US Food and Drug Administration (USFDA) to market Olmesartan Medoxomil tablets in the US market.
The approval will allow the company to sell the drug in strengths of 5 mg, 20 mg and 40 mg. This is a day-one approval after the expiry of 181-day exclusivity, Zydus said here.
The drug is an anti-hypertensive and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
The estimated sales for Olmesartan is $982 million (IMS MAT February 2017), it added.
Businessline
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…